Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

The study found Blenrep had no notable effects on progression-free survival, ... good for 59% year-over-year growth. GSK multiple myeloma Blenrep CAR-T Clinical Data Pharma. Connect. The Team; ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

FDA Approves GSK’s BLENREP ... The effects were not reversible in male rats but were reversible in female rats. Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult ...

Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first treatment didn’t work or who had severe side effects.

The most common side effects with Blenrep include reduced visual acuity, corneal examination abnormalities (including keratopathy), thrombocytopenia, blurred vision, dry eye, foreign-body ...